通心络及稳心颗粒联合倍他乐克治疗冠心病心绞痛临床疗效研究

Study on clinical efficacy of Tongxinluo and Wenxin granule combined with betaloc in the treatment of angina pectoris of coronary heart disease

目的探究通心络胶囊及稳心颗粒联合倍他乐克治疗冠心病心绞痛临床疗效。方法 68例冠心病心绞痛患者,采用随机数字表法分为研究组与对照组,各34例。对照组采取常规药物治疗,研究组在对照组治疗基础上采用通心络胶囊及稳心颗粒联合倍他乐克治疗,对比两组患者治疗效果及治疗后血脂指标水平。结果研究组患者治疗总有效率为100.00%,明显高于对照组的88.24%,差异具有统计学意义(χ2=4.2500,P<0.05)。治疗后研究组甘油三酯(TG)、总胆固醇(TC)、高密度脂蛋白(HDL)、低密度脂蛋白(LDL)水平均优于对照组,差异具有统计学意义(t=12.6672、3.8994、3.5819、3.5725,P<0.05)。结论通心络胶囊及稳心颗粒联合倍他乐克治疗冠心病心绞痛临床疗效显著,可推广应用。

Objective To investigate the clinical efficacy of Tongxinluo capsule and Wenxin granule combined with betaloc in the treatment of angina pectoris of coronary heart disease. Methods A total of 68 angina pectoris of coronary heart disease patients were divided by random number table into research group and control group, with 34 cases in each group. The control group was treated with conventional drugs, and the research group was treated with Tongxinluo capsule, Wenxin granule and betaloc on the basis of the control group. Comparison were made on treatment effect and blood lipid levels after treatment between two groups. Results The research group had obviously higher total treatment effective rate as 100.00% than 88.24% in the control group, and the difference was statistically significant （X2=4.2500, P〈0.05）. After treatment, the research group had better triglyceride （TG）, cholesterol （TC）, high-density lipoprotein （HDL）, and low-density lipoprotein （LDL） levels than the control group, and their difference was statistically significant （t=12.6672, 3.8994, 3.5819, 3.5725, P〈0.05）. Conclusion Tongxinluo capsule and Wenxin granule combined with betaloc shows remarkable clinical efficacy in treating angina pectoris of coronary heart disease, and this method can be promoted and applied.